Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma

被引:45
作者
Zu, YL
Steinberg, SM
Campo, E
Hans, CP
Weisenburger, DD
Braziel, RM
Delabie, J
Gascoyne, RD
Muller-Hermlink, K
Pittaluga, S
Raffeld, M
Chan, WC
Jaffe, ES
机构
[1] NCI, Hematopathol Sect, Pathol Lab, Ctr Canc Res, Bethesda, MD 20892 USA
[2] NCI, Biostat & Data Management Sect, Off Clin Director, Ctr Canc Res, Bethesda, MD USA
[3] Univ Barcelona, Pathol Lab, Hosp Clin, Barcelona, Spain
[4] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE USA
[5] Oregon Hlth Sci Univ, Dept Pathol, Portland, OR USA
[6] Norwegian Radium Hosp, Oslo, Norway
[7] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[8] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany
关键词
validation; monoclonal antibodies; tissue microarray; immunohistochemistry; diffuse large B-cell lymphoma; prognostic markers;
D O I
10.1080/10428190500051844
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tissue microarrays (TMAs) show concordance with whole tissue sections in the immunohistochemical evaluation of tumor cells. However, potential inter-institutional variability among observers and immunohistochemical staining methods has not been fully addressed. We selected 21 cases of diffuse large B-cell lymphoma (DLBCL) to process for TMAs. Immunohistochemical stains were performed in 3 laboratories, and reviewed independently by 3 hematopathologists at the 3 institutions. Stains were scored on a 4-point scale. Statistical analyses of variation in the scoring among observers and among different institutions' stains were performed. Stains for CD3, CD10, CD20, BCL-2, BCL-6, MIB-1, and FOX-P1 revealed little variation among observers, with an average 51-82% complete agreement and 82-100% agreement +/- 1 numerical score. The rate of concordance when evaluating most stains performed in different laboratories was also relatively good, with an average of 55-72% complete agreement and 70-97% agreement +/- 1 score. However, scoring of MUM-1 and p53 stains showed wider variation, with an average of only 37 and 30% complete agreement among observers, and 11 and 45% agreement when stains from different institutions were examined. Further statistical analyses were performed to compare the observers' scoring of their own institution's stains (self-review) vs. observers' scoring of other institutions' stains (non-self). The agreement rate for the p53 stain was significantly higher when based on self-review (average 58% complete agreement) compared with an agreement rate of only 10.5% when based on a review of stains performed in another laboratory, non-self review, P < 0.01. This difference in the self- vs. non-self review was not seen when data for MUM-1 were analysed. In conclusion, most phenotypic markers used in the analysis of DLBCL can be evaluated in TMAs with adequate agreement among observers and laboratories. These include CD3, CD20, CD10, BCL-2, BCL-6, MIB-1, and FOX-P1. However, some markers, such as p53 and MUM-1, are more prone to inter-institutional variation. Variations in interpretation can be partially overcome by self- adjusted/adapt tendency, as seen with p53. Especially with newly developed markers, such as MUM-1, the development of standardized techniques for staining and interpretation is critical to reduce inter-observer variability.
引用
收藏
页码:693 / 701
页数:9
相关论文
共 37 条
[1]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[2]   Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma [J].
Barrans, SL ;
Carter, I ;
Owen, RG ;
Davies, FE ;
Patmore, RD ;
Haynes, AP ;
Morgan, GJ ;
Jack, AS .
BLOOD, 2002, 99 (04) :1136-1143
[3]   Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[4]   Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma [J].
Chang, CC ;
McClintock, S ;
Cleveland, RP ;
Trzpuc, T ;
Vesole, DH ;
Logan, B ;
Kajdacsy-Balla, A ;
Perkins, SL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2004, 28 (04) :464-470
[5]   Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma [J].
Colomo, L ;
Löpez-Guillermo, A ;
Perales, M ;
Rives, S ;
Martínez, A ;
Bosch, F ;
Colomer, D ;
Falini, B ;
Montserrat, E ;
Campo, E .
BLOOD, 2003, 101 (01) :78-84
[6]   ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia [J].
Crespo, M ;
Bosch, F ;
Villamor, N ;
Bellosillo, B ;
Colomer, D ;
Rozman, M ;
Marcé, S ;
López-Guillermo, A ;
Campo, E ;
Montserrat, E .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (18) :1764-1775
[7]   Evaluation of the interobserver reproducibility of Gleason grading of prostatic adenocarcinoma using tissue microarrays [J].
De la Taille, A ;
Viellefond, A ;
Berger, N ;
Boucher, E ;
De Fromont, M ;
Fondimare, A ;
Molinié, V ;
Piron, D ;
Sibony, M ;
Staroz, F ;
Triller, M ;
Peltier, E ;
Thiounn, N ;
Rubin, MA .
HUMAN PATHOLOGY, 2003, 34 (05) :444-449
[8]   Diffuse large B-cell lymphoma of bone - An analysis of differentiation-associated antigens with clinical correlation [J].
de Leval, L ;
Braaten, KM ;
Ancukiewicz, M ;
Kiggundu, E ;
Delaney, T ;
Mankin, HJ ;
Harris, NL .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (09) :1269-1277
[9]   A monoclonal antibody (MUM1p) detects expression of the MUM 1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells [J].
Falini, B ;
Fizzotti, M ;
Pucciarini, A ;
Bigerna, B ;
Marafioti, T ;
Gambacorta, M ;
Pacini, R ;
Alunni, C ;
Natali-Tanci, L ;
Ugolini, B ;
Sebastiani, C ;
Cattoretti, G ;
Pileri, S ;
Dalla-Favera, R ;
Stein, H .
BLOOD, 2000, 95 (06) :2084-2092
[10]   Hodgkin and Reed-Stemberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints:: analyses using tissue microarrays [J].
García, JF ;
Camacho, FI ;
Morente, M ;
Fraga, M ;
Montalbán, C ;
Alvaro, T ;
Bellas, C ;
Castaño, A ;
Díez, A ;
Flores, T ;
Martín, C ;
Martínez, MA ;
Mazorra, F ;
Menárguez, J ;
Mestre, MJ ;
Mollejo, M ;
Sáez, AI ;
Sánchez, L ;
Piris, MA .
BLOOD, 2003, 101 (02) :681-689